文献速递冠心病

血流储备分数与冠心病心脏事件:IRIS-FFR前瞻性注册研究

Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve).
PubMed 文献 · Circulation · 2017-03-29

IRIS-FFR前瞻性注册研究纳入5846例患者,对6468处病变延迟血运重建、2165处病变行血运重建。中位随访1.9年,延迟病变中FFR值与主要不良心脏事件风险呈线性负相关;FFR≤0.75的病变血运重建优于延迟,FFR≥0.76的病变药物治疗合理安全。

要点

  • 延迟病变中FFR值与主要不良心脏事件风险显著负相关(校正HR 1.06)。
  • FFR≤0.75的病变血运重建后事件风险显著低于延迟病变。
  • FFR≥0.76的病变延迟与血运重建的事件风险无显著差异。

核心结论

  • 大型前瞻性注册研究显示,延迟病变中FFR值与心脏事件风险呈线性相关。
  • FFR≤0.75的冠状动脉狭窄血运重建结局优于延迟血运重建。
  • FFR≥0.76的狭窄药物治疗是合理且安全的治疗策略。

研究设计与样本

  • IRIS-FFR前瞻性注册研究纳入5846例至少一处冠状动脉病变行FFR测量的患者。
  • 6468处病变延迟血运重建,2165处病变行血运重建。
  • 主要终点为中位随访1.9年的主要不良心脏事件(心源性死亡、心肌梗死和再次血运重建),按病变分析。
  • 采用边际Cox模型处理多病变患者的相关数据,并校正混杂因素。

主要发现

  • 延迟病变中,主要不良心脏事件风险与FFR呈显著负相关(校正HR 1.06,95%CI 1.05-1.08,P<0.001)。
  • 血运重建病变中未观察到该关系(校正HR 1.00,95%CI 0.98-1.02,P=0.70)。
  • FFR≥0.76的病变,延迟与血运重建的主要不良心脏事件风险无显著差异。
  • FFR 0.71-0.75的病变,血运重建的主要不良心脏事件风险显著低于延迟(校正HR 0.47,95%CI 0.24-0.89,P=0.021)。
  • FFR≤0.70的病变,血运重建的主要不良心脏事件风险显著低于延迟(校正HR 0.47,95%CI 0.26-0.84,P=0.012)。

关键数值与推荐

  • 延迟病变中FFR与主要不良心脏事件风险:校正HR 1.06(95%CI 1.05-1.08,P<0.001)。
  • 血运重建病变中FFR与主要不良心脏事件风险:校正HR 1.00(95%CI 0.98-1.02,P=0.70)。
  • FFR 0.71-0.75病变血运重建 vs 延迟:校正HR 0.47(95%CI 0.24-0.89,P=0.021)。
  • FFR≤0.70病变血运重建 vs 延迟:校正HR 0.47(95%CI 0.26-0.84,P=0.012)。

临床怎么用

  • FFR≤0.75的冠状动脉狭窄,血运重建与延迟相比主要不良心脏事件风险更低。
  • FFR≥0.76的狭窄,药物治疗是合理且安全的治疗策略。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the prognosis of deferred and revascularized coronary stenoses after fractional flow reserve (FFR) measurement to assess its revascularization threshold in clinical practice. METHODS: The IRIS-FFR registry (Interventional Cardiology Research In-cooperation Society Fractional Flow Reserve) prospectively enrolled 5846 patients with ≥1coronary lesion with FFR measurement. Revascularization was deferred in 6468 lesions and performed in 2165 lesions after FFR assessment. The primary end point was major adverse cardiac events (cardiac death, myocardial infarction, and repeat revascularization) at a median follow-up of 1.9 years and analyzed on a per-lesion basis. A marginal Cox model accounted for correlated data in patients with multiple lesions, and a model to predict per-lesion outcomes was adjusted for confounding factors. RESULTS: For deferred lesions, the risk of major adverse cardiac events demonstrated a significant, inverse relationship with FFR (adjusted hazard ratio, 1.06; 95% confidence interval, 1.05-1.08; P<0.001). However, this relationship was not observed in revascularized lesions (adjusted hazard ratio, 1.00; 95% confidence interval, 0.98-1.02; P=0.70). For lesions with FFR ≥0.76, the risk of major adverse cardiac events was not significantly different between deferred and revascularized lesions. Conversely, in lesions with FFR ≤0.75, the risk of major adverse cardiac events was significantly lower in revascularized lesions than in deferred lesions (for FFR 0.71-0.75, adjusted hazard ratio, 0.47; 95% confidence interval, 0.24-0.89; P=0.021; for FFR ≤0.70, adjusted hazard ratio 0.47; 95% confidence interval, 0.26-0.84; P=0.012). CONCLUSIONS: This large, prospective registry showed that the FFR value was linearly associated with the risk of cardiac events in deferred lesions. In addition, revascularization for coronary artery stenosis with a low FFR (≤0.75) was associated with better outcomes than the deferral, whereas for a stenosis with a high FFR (≥0.76), medical treatment would be a reasonable and safe treatment strategy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01366404.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ahn JM, Park DW, Shin ES, et al. Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). Circulation. 2017. PMID: 28356440. doi:10.1161/CIRCULATIONAHA.116.024433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。